Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule-Reference-Cited by-同舟云学术

Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule

Published:2019-05-01 Issue:5 Volume:42 Page:786-791
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Hirata Kenshiro¹,Watanabe Hiroshi²³,Toyoda Mariko⁴,Sugimoto Ryusei²,Ikegami Komei²,Imafuku Tadashi²,Matsuzaka Kotaro²,Ichimizu Shota²,Maeda Hitoshi²³,Uekihara Sohichi⁴,Jingami Sachiko²,Maruyama Toru²³

Affiliation:

1. Department of Pharmacy, Japanese Red Cross Kumamoto Hospital

2. Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University

3. Center for Clinical Pharmaceutical Sciences, School of Pharmacy, Kumamoto University

4. Department of General Internal Medicine, Japanese Red Cross Kumamoto Hospital

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/42/5/42_b18-00976/_pdf

Reference30 articles.

1. 1) Miyamoto Y, Iwao Y, Mera K, Watanabe H, Kadowaki D, Ishima Y, Chuang VT, Sato K, Otagiri M, Maruyama T. A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate. Biochem. Pharmacol., 84, 1207–1214 (2012).

2. 2) de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther. Drug Monit., 31, 416–435 (2009).

3. 3) Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin. Drug Metab. Toxicol., 13, 1225–1236 (2017).

4. 4) Spriet I, Grootaert V, Meyfroidt G, Debaveye Y, Willems L. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug–drug interaction. Eur. J. Clin. Pharmacol., 69, 737–738 (2013).

5. 5) Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y. Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br. J. Clin. Pharmacol., 66, 154–155 (2008).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms;British Journal of Clinical Pharmacology;2023-08-22

2. Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease;Drug Design, Development and Therapy;2022-07

3. Response to “iPTH is not a significant factor influencing the tacrolimus C/D ratio”;Clinical and Translational Science;2022-02-19

4. iPTH is not a significant factor influencing the tacrolimus C/D ratio;Clinical and Translational Science;2022-02-14

5. Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia;Molecular Pharmaceutics;2021-11-04